PROPIONATE DE FLUTICASONE TEVA 250 micrograms/dose, suspension for inhalation in a pressurised container 120 doses
Active ingredients: Fluticasone propionate
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for inhalation120 dosesinhalée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PROPIONATE DE FLUTICASONE TEVA 250 microgrammes/dose, suspension pour inhalation en flacon pressurisé
- Pharmaceutical form
- suspension pour inhalation
- Route of administration
- inhalée
- Presentation description
- 1 flacon pressurisé aluminium avec valve doseuse avec embout buccal de 120 doses
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Dec 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68250875CIP73016314CIP133400930163146Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PROPIONATE DE FLUTICASONEsuspension | 250 microgrammes · une dose émise par la valve | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.